First Horizon Corporation Common Stock vs uniQure N.V. Ordinary Shares — how do they compare? First Horizon Corporation Common Stock trades at $22.63 (market cap $10.79B), while uniQure N.V. Ordinary Shares trades at $20.78 (market cap $1.48B). The key difference: First Horizon Corporation Common Stock is far larger — about 7.3× uniQure N.V. Ordinary Shares's market cap, and First Horizon Corporation Common Stock pays a 2.99% dividend while uniQure N.V. Ordinary Shares pays none. Which is the better fit depends on your goals — on Pluang, investors hold First Horizon Corporation Common Stock for 0 Days and uniQure N.V. Ordinary Shares for 0 Days on average.
| FHN | QURE | |
|---|---|---|
Market Cap | $10.79B | $1.48B |
Volume | 8,579,466 | 2,488,780 |
Sector | Financials | Health |
52-Week High | $26.23 | $70.59 |
52-Week Low | $19.94 | $9.03 |
Typical Hold Time | 0 Days | 0 Days |
Enterprise Value | $14.10B | $728.62M |
Dividend Yield | 2.99% | — |
Signals from Pluang's Aura AI — not financial advice
First Horizon (FHN) trades at $22.77, down 1.26% on the day, with a neutral technical outlook. The stock shows strong fundamentals, including a P/E of 10.95 and net income margin of 30.87% for 2026, supported by three consecutive quarterly earnings beats. Recent news highlights executive recognitions and upcoming Q3 2026 earnings on October 15, 2026.
The outlook is positive given robust profitability, analyst consensus price target of $27.44 (20.5% upside), and no sell ratings. Risks include high debt-to-asset ratio of 1.81 and macroeconomic sensitivity. Earnings growth remains the key catalyst for further upside, with investor focus on Q3 results.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
First Horizon Corporation is the holding company for First Horizon Bank, a regional financial services provider operating roughly 460 branches across 11 states in southeastern US. It offers commercial, consumer, private banking, wealth management, and capital markets services.
Read more on FHN →uniQure N.V. is a biotechnology company that develops gene therapies for rare and severe genetic diseases, marketing HEMGENIX for hemophilia B and advancing its AAV-based miQURE platform in programs such as AMT-130 for Huntington's disease.
Read more on QURE →